Clinical Trial Update: Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating the anti-TNF agent adalimumab for reducing inflammation in axial spondyloarthritis, including ankylosing spondylitis.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Axial Spondyloarthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: University of Helsinki | Conditions: Ankylosing Spondyloarthritis | Phase 4 | Status: UNKNOWN